Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/21762967

Download in:

View as

General Info

PMID
21762967